210 related articles for article (PubMed ID: 22542812)
21. Using electronic health records to evaluate the adherence to cervical cancer prevention guidelines: A cross-sectional study.
Mooses K; Šavrova A; Pajusalu M; Oja M; Tamm S; Haug M; Padrik L; Laanpere M; Uusküla A; Kolde R
Prev Med; 2024 Jun; 183():107982. PubMed ID: 38701952
[TBL] [Abstract][Full Text] [Related]
22. Use of electronic medical record-based tools to improve compliance with cervical cancer screening guidelines: effect of an educational intervention on physicians' practice patterns.
White P; Kenton K
J Low Genit Tract Dis; 2013 Apr; 17(2):175-81. PubMed ID: 23343700
[TBL] [Abstract][Full Text] [Related]
23. Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens.
Mangold BR
Acta Cytol; 2019; 63(5):379-384. PubMed ID: 31035279
[TBL] [Abstract][Full Text] [Related]
24. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of Screening Tools for Pap Smears in General Practice.
Harding C; Seal A; Pilotto L; Mackey K; Duncan G; Huynh R; McWilliam R; Blake S
J Innov Health Inform; 2016 Sep; 23(3):835. PubMed ID: 28059690
[TBL] [Abstract][Full Text] [Related]
26. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
27. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
[TBL] [Abstract][Full Text] [Related]
28. Validating self-reported cervical cancer screening among women leaving jails.
Webb S; Kelly PJ; Wickliffe J; Ault K; Ramaswamy M
PLoS One; 2019; 14(7):e0219178. PubMed ID: 31260465
[TBL] [Abstract][Full Text] [Related]
29. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of adjunctive tests for cervical cancer screening in low resource settings.
Bhatla N; Mukhopadhyay A; Kriplani A; Pandey RM; Gravitt PE; Shah KV; Iyer VK; Verma K
Indian J Cancer; 2007; 44(2):51-5. PubMed ID: 17938481
[TBL] [Abstract][Full Text] [Related]
31. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
[TBL] [Abstract][Full Text] [Related]
32. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.
Yabroff KR; Saraiya M; Meissner HI; Haggstrom DA; Wideroff L; Yuan G; Berkowitz Z; Davis WW; Benard VB; Coughlin SS
Ann Intern Med; 2009 Nov; 151(9):602-11. PubMed ID: 19884621
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus screening and cervical cancer prevention.
Sasieni PD
J Am Med Womens Assoc (1972); 2000; 55(4):216-9. PubMed ID: 10935355
[TBL] [Abstract][Full Text] [Related]
34. Cervical Cancer Screening Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs Versus Provider-Administered Pap Tests.
McDowell M; Pardee DJ; Peitzmeier S; Reisner SL; Agénor M; Alizaga N; Bernstein I; Potter J
LGBT Health; 2017 Aug; 4(4):252-259. PubMed ID: 28665783
[TBL] [Abstract][Full Text] [Related]
35. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.
Rozendaal L; Walboomers JM; van der Linden JC; Voorhorst FJ; Kenemans P; Helmerhorst TJ; van Ballegooijen M; Meijer CJ
Int J Cancer; 1996 Dec; 68(6):766-9. PubMed ID: 8980181
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
[TBL] [Abstract][Full Text] [Related]
37. Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
Miller RA; Mody DR; Tams KC; Thrall MJ
Arch Pathol Lab Med; 2015 Nov; 139(11):1431-6. PubMed ID: 25951104
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
Mayrand MH; Duarte-Franco E; Rodrigues I; Walter SD; Hanley J; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
N Engl J Med; 2007 Oct; 357(16):1579-88. PubMed ID: 17942871
[TBL] [Abstract][Full Text] [Related]
39. Review of electronic decision-support tools for diabetes care: a viable option for low- and middle-income countries?
Ali MK; Shah S; Tandon N
J Diabetes Sci Technol; 2011 May; 5(3):553-70. PubMed ID: 21722571
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
